Comprehensive safety evaluation of isatuximab in multiple myeloma using disproportionality analysis of FAERS and meta-analysis of randomized controlled trials
Abstract Isatuximab, an anti-CD38 monoclonal antibody, has been shown to induce apoptosis in multiple myeloma (MM) cells and is effective in both relapsed/refractory and newly diagnosed MM cases. This study aims to compare the safety profile of isatuximab by examining a broader range of adverse even...
Saved in:
| Main Authors: | Muhammed Favas Karimbanathottathil, Beema T Yoosuf, M Mamatha, Dipika Bansal |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2024-12-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-024-83014-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Isatuximab in the treatment of refractory and relapsed multiple myeloma: literature review and case report
by: Yu. E. Ryabukhina, et al.
Published: (2023-12-01) -
Subcutaneous administration of isatuximab in patients with multiple myeloma by an on-body delivery system: results of a nurse survey
by: Nuria Sánchez Avello, et al.
Published: (2025-06-01) -
CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells
by: Hongjie Wang, et al.
Published: (2024-12-01) -
Disproportionality analysis of oesophageal toxicity associated with oral bisphosphonates using the FAERS database (2004–2023)
by: Lin Chen, et al.
Published: (2024-11-01) -
A systematic review and meta-analysis of phase III randomized controlled trials to assess the risk of pneumonia, URTIs, and VTE in multiple myeloma patients treated with isatuximab
by: Daniel Thomas Jones, et al.
Published: (2025-03-01)